Enhanced expression of miR-375 increases chemotherapy sensitivity of prostate cancer to cisplatin

Objectives: Prostate cancer (PCa) is one of the most common malignancies in men. This study is to determine if human miR-375 affects the effect of cisplatin on PCa. Methods: Prostate cancer tissue samples were obtained during urological surgery from 10 patients. The adjacent normal tissues were collected during surgeries and served as the control sample groups. Real-time PCR, MTT assay, flow cytometry, and transwell chamber invasion assay were performed to detect the effects of transfected miR-375 analogs on the cells in combination with treatment of cisplatin. Results: The miR-375 levels were significantly decreased in PCa tissues when compared with the adjacent normal tissues. miR-375 analog nucleotide and cisplatin treatment significantly decreased cell survival rates (p < 0.05), suggesting that miR-375 increases the chemotherapy sensitivity of PCa cells to cisplatin. Additionally, miR-375 analog nucleotide and cisplatin significantly increased apoptosis rate and decreased cell invasion ability of PCa cells (p < 0.05). Conclusion: miR-375 analog nucleotide can increase the chemotherapy sensitivity of PCa cells to cisplatin, resulting in a synergistic effect by inducing apoptosis and reducing the cancer cell invasion ability.